DAWN实时信号 | 通过Getagraph.com最大化利润

购买 107367 min ago

@ $14.66

发出时间: 15 Feb 2024 @ 04:53

回报率: 1.77%

上一信号: Feb 14 - 22:31

上一信号: 出售

回报率: 1.24 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers...

Stats
今日成交量	3.60M
平均成交量	966 801
市值	1.30B
EPS	$0 ( 2024-03-04 )
下一个收益日期	( $-0.670 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.30
ATR14	$0.0500 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Blackman Samuel C.	Sell	10 000	Common Stock
2024-03-25	Blackman Samuel C.	Sell	10 000	Common Stock
2024-03-11	Blackman Samuel C.	Sell	30 000	Common Stock
2024-02-27	Blackman Samuel C.	Sell	20 000	Common Stock
2024-02-15	Dubow Adam	Sell	3 687	Restricted Stock Unit (RSU)

INSIDER POWER
46.99
Last 98 transactions
Buy: 3 591 581 \| Sell: 1 422 797

音量相关性

長: 0.18 (neutral)

短: -0.80 (moderate negative)

Signal:(47.978) Neutral

Day One 相关性

10 最正相关
CASA	0.96
ESPR	0.953
ALT	0.952
KZR	0.952
SONN	0.95
ACER	0.949
MRBK	0.949
AHPI	0.948
IOBT	0.944
PFSW	0.943

10 最负相关
STAY	-0.966
DSPG	-0.963
DVCR	-0.947
LMNX	-0.947
OPNT	-0.942
RAM	-0.94
NTUS	-0.935
AMYT	-0.935
COCO	-0.928
CPTA	-0.928

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Day One 相关性 - 货币/商品

0.30
( neutral )

-0.05
( neutral )

0.00
( neutral )

-0.44
( neutral )

0.21
( neutral )

0.01
( neutral )

Day One 财务报表

Annual	2023
营收:	$0
毛利润:	$-383 000 (0.00 %)
EPS:	$-2.37

FY	2023
营收:	$0
毛利润:	$-383 000 (0.00 %)
EPS:	$-2.37

FY	2022
营收:	$0
毛利润:	$-531 000 (0.00 %)
EPS:	$-2.02

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-4.62

Financial Reports:

No articles found.

Day One

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.